197 related articles for article (PubMed ID: 11106246)
1. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer.
Holten-Andersen MN; Stephens RW; Nielsen HJ; Murphy G; Christensen IJ; Stetler-Stevenson W; Brünner N
Clin Cancer Res; 2000 Nov; 6(11):4292-9. PubMed ID: 11106246
[TBL] [Abstract][Full Text] [Related]
2. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
4. Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer.
Holten-Andersen MN; Murphy G; Nielsen HJ; Pedersen AN; Christensen IJ; Høyer-Hansen G; Brünner N; Stephens RW
Br J Cancer; 1999 May; 80(3-4):495-503. PubMed ID: 10408859
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Imada T; Noguchi Y
Anticancer Res; 2004; 24(3b):2101-5. PubMed ID: 15274408
[TBL] [Abstract][Full Text] [Related]
6. Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer.
Sørensen NM; Schrohl AS; Jensen V; Christensen IJ; Nielsen HJ; Brünner N
Scand J Gastroenterol; 2008; 43(2):186-91. PubMed ID: 18224564
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Pahl H; Fateh-Moghadam A
Anticancer Res; 1997; 17(4B):2935-8. PubMed ID: 9329568
[TBL] [Abstract][Full Text] [Related]
8. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer.
Kos J; Nielsen HJ; Krasovec M; Christensen IJ; Cimerman N; Stephens RW; Brünner N
Clin Cancer Res; 1998 Jun; 4(6):1511-6. PubMed ID: 9626470
[TBL] [Abstract][Full Text] [Related]
10. Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Takemiya S; Yanoma S; Noguchi Y; Takanashi Y
Br J Surg; 2001 Dec; 88(12):1596-601. PubMed ID: 11736971
[TBL] [Abstract][Full Text] [Related]
11. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis.
Kos J; Krasovec M; Cimerman N; Nielsen HJ; Christensen IJ; Brünner N
Clin Cancer Res; 2000 Feb; 6(2):505-11. PubMed ID: 10690531
[TBL] [Abstract][Full Text] [Related]
12. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
13. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
[TBL] [Abstract][Full Text] [Related]
14. Impact of plasma tissue inhibitor of matrix metalloproteinase-1 on long-term survival in patients with colorectal cancer.
Yukawa N; Yoshikawa T; Akaike M; Sugimasa Y; Rino Y; Masuda M; Imada T
Oncology; 2007; 72(3-4):205-8. PubMed ID: 18160809
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma TIMP-1 levels after resection for primary colorectal cancer.
Frederiksen C; Lomholt AF; Davis GJ; Dowell BL; Blankenstein MA; Christensen IJ; Brünner N; Nielsen HJ
Anticancer Res; 2009 Jan; 29(1):75-81. PubMed ID: 19331135
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) in colorectal cancer patients.
Ishida H; Murata N; Hayashi Y; Tada M; Hashimoto D
Surg Today; 2003; 33(12):885-92. PubMed ID: 14669077
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of plasma level of vascular endothelial growth factor-C in patients with colorectal cancer.
Miyazaki T; Okada N; Ishibashi K; Ogata K; Ohsawa T; Ishiguro T; Nakada H; Yokoyama M; Matsuki M; Kato H; Kuwano H; Ishida H
Jpn J Clin Oncol; 2008 Dec; 38(12):839-43. PubMed ID: 18923001
[TBL] [Abstract][Full Text] [Related]
18. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
[TBL] [Abstract][Full Text] [Related]
19. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
20. Elevated plasma tissue inhibitor of metalloproteinase-1 level predicts decreased response and survival in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Evans DB; Hamer P; Brown-Shimer S; Pierce K; Carney W
Cancer; 2007 May; 109(10):1933-9. PubMed ID: 17407159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
